第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。SABCS是全球最大的乳腺癌领域盛会，来自102个国家的超过1万名注册参会者将在为期四天的会议中展示1886篇被接受的论文摘要。肿瘤瞭望特别整理中国专家被收录的壁报内容，以飨读者。
编者按：第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。SABCS是全球最大的乳腺癌领域盛会，来自102个国家的超过1万名注册参会者将在为期四天的会议中展示1886篇被接受的论文摘要。肿瘤瞭望特别整理中国专家被收录的壁报内容，以飨读者。（注：因官网未公布详细作者单位，如有遗漏或错误，欢迎留言指正。）
Poster Session 2
日期：12月11日
时间：5:30～7:00 p.m.
地点：Halls 2-3
P2-01-23:A 140-gene Machine Learning Classifier Predicts Survival and Response to Chemotherapy and Immunotherapy in 2500 TNBC
一个包含140个基因的机器学习分类器预测了2500例三阴性乳腺癌（TNBC）患者的生存率以及对化疗和免疫治疗的反应
报告作者：Xixuan Zhu
P2-02-09:Novel Intramolecular BRCT Domain Interaction with ECT2 C-terminal Intramolecular Interaction Domain Regulates GEF Activity and Tumorigenesis
新型分子内BRCT结构域与ECT2 C端分子内相互作用结构域相互作用调节GEF活性和肿瘤发生
报告作者：Jinyu Lu
P2-02-11:Unveiling the subtype-specific role of PTPRK in triplenegative breast cancer:Implications for targeted therapies
揭示PTPRK在三阴性乳腺癌中的亚型特异性作用：对靶向治疗的启示
报告作者：Xiangyi Liu
P2-02-14:C1QL1 inhibits breast cancer through HSP90α/VCPERS/UPR axis
C1QL1通过HSP90α/VCPERS/UPR轴抑制乳腺癌
报告作者：Ningning Zhang
P2-02-15:Engineered macrophages secreting TRAIL achieve immunotherapy for triple-negative breast cancer by inhibiting the Wnt/β-catenin signaling pathway
分泌TRAIL的巨噬细胞通过抑制Wnt/β-catenin信号通路实现对三阴性乳腺癌的免疫治疗
报告作者：Chuangui Song
P2-02-19:Virtual Multiplex Immunofluorescence Identifies Lymphocyte Subsets Predictive of Response to Neoadjuvant Therapy
虚拟多重免疫荧光识别淋巴细胞亚群预测对新辅助治疗的应答
报告作者：Anran Li
P2-02-20:Prediction of Axillary Lymph Node Metastasis in Breast Cancer using Intraoperative Fluorescence Multi-modal Imaging
术中荧光多模态成像对乳腺癌腋窝淋巴结转移的预测
报告作者：He Sun
P2-03-17:Targeting NR2F2 overcomes multiple forms of endocrine resistance
靶向NR2F2可克服多种形式的内分泌耐药
报告作者：Yanyan Cai
P2-03-18:Lymph node metastasis of breast cancer:subclonal selection for high lipid metabolism from the primary tumor
乳腺癌淋巴结转移：原发肿瘤高脂代谢的亚克隆选择
报告作者：Yue Zhou
P2-04-02:TRIB3 regulates lipophagy and drives the metastasis of triple negative breast cancer by activation of PI3K/AKT/mTOR pathway
TRIB3通过激活PI3K/AKT/mTOR通路调控脂噬，进而驱动三阴性乳腺癌的转移
报告作者：zirong jiang
P2-04-04:Integrated stress response-upregulated mitochondrial SLC1A5var enhances glucose dependency of human breast cancer cells
整合应激反应上调的线粒体SLC1A5增强了人乳腺癌细胞的葡萄糖依赖
报告作者：Sheng-Fan Wan
P2-04-07:Dual function of PRAK in TP53-associated breast cancer metastasis
PRAK在tp53相关乳腺癌转移中的双重功能
报告作者：Jingjing Liu
P2-04-08:Functions of KLF5 in the cell cycle and breast cancer cell Proliferation
KLF5在细胞周期和乳腺癌细胞增殖中的作用
报告作者：Xiaoyun Mao
P2-04-09:A Novel Role of IP6K2 in Regulating Host Cell Death through p21-mediated cell cycle arrest during HSV-1 oncolytic virus Therapy
在HSV-1溶瘤病毒治疗过程中，IP6K2通过p21介导的细胞周期阻滞调控宿主细胞死亡的新作用
报告作者：Zhijian Huang
P2-04-10:ARL3 Promotes Hormone Receptor Positive Breast Cancer Progression and Tamoxifen Resistance through ERαStablization
ARL3通过ERα稳定促进激素受体阳性乳腺癌进展和他莫昔芬耐药
报告作者：Han Li
P2-04-11:Selective Pre-clinical Targeting of CD44+ADAR1+Triple Negative Breast Cancer
针对CD44+ADAR1+三阴性乳腺癌的选择性临床前靶向治疗
报告作者：Wenxue Ma
P2-04-12:JAM A expression and its clinical/prognostic value in breast cancer
JAM A在乳腺癌中的表达及其临床预后价值
报告作者：Yufei Lou
P2-04-19:Identification and Validation of Novel Necroptosis-Related lncRNAs for Prognostic Prediction in Breast Cancer
乳腺癌中新型坏死性凋亡相关长链非编码RNA的鉴定及其预后预测验证
报告作者：Zhijian Huang
P2-04-25:Different Pyroptosis Phenotype within Breast Cancer Possess Distinctive Prognosis and Tumor Immune Microenvironment
乳腺癌中不同的细胞焦亡表型具有不同的预后和肿瘤免疫微环境
报告作者：Ye Hong
P2-04-26:Predicting the prognosis and immunotherapeutic response of triplenegative breast cancer by constructing a prognostic model based on CD8T cellrelated immune genes
基于CD8+T细胞相关免疫基因构建预后模型预测三阴性乳腺癌的预后及免疫治疗反应
报告作者：Zhijian Huang
P2-04-29:Predictive model of prognosis index for invasive micropapillary carcinoma of the breast based on machine learning:A SEER population-based study
基于机器学习的乳腺浸润性微乳头状癌预后指数预测模型：一项基于SEER人群的研究
报告作者：zirong jiang
P2-05-10:Depression and anxiety in patients with breast cancer receiving radiotherapy:A prospective longitudinal study
接受放疗的乳腺癌患者的抑郁和焦虑情况：一项前瞻性纵向研究
报告作者：Shi-Jia Wang
P2-05-11:A prospective cohort study of real-world patientreported outcomes in HER2-positive early breast cancer patients receiving(neo)adjuvant anti-HER2 based therapy:the preliminary results at 2-cycle treatment
一项关于接受（新）辅助抗HER2治疗方案的HER2阳性早期乳腺癌患者真实世界患者报告结局的前瞻性队列研究：2周期治疗后的初步结果
报告作者：Ke-Da YU
P2-05-19:An ICG-labeled Novel Trop2 Targeting Peptide for In Vivo and Ex Vivo NIR-II Fluorescence Imaging-guided Breast Cancer Precise Surgery
一种ICG标记的新型Trop2靶向肽，用于体内和离体NIR-II荧光成像引导的乳腺癌精准手术
报告作者：Kangliang Lou
P2-05-25:Comparative Study of Droplet-digital PCR and Ultrasensitive NGS Assay for ctDNA Profiling in Breast Cancer
乳腺癌ctDNA特征分析：液滴数字PCR与超灵敏NGS检测的比较研究
报告作者：Binggang Xiang
P2-05-27:Revealing prognostic subtypes and related model of early-stage TNBC
揭示早期三阴性乳腺癌的预后亚型及相关模型
报告作者：Peifen FU
P2-06-01:CBP/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in TNBC
CBP/P300溴结构域抑制可减少三阴性乳腺癌中的中性粒细胞积聚并激活抗肿瘤免疫
报告作者：Xueying Yuan
P2-06-12:MGAT1-Mediated Glycosylation Orchestrates Immune Checkpoints and Antitumor Immunity
MGAT1介导的糖基化调控免疫检查点和抗肿瘤免疫
报告作者：Junlong Chi
P2-06-14:Calcium-Sensing Receptor Agonist Enhanced AntiTumor Activity of Adoptive NK Cell Therapy in Triple-Negative Breast Cancer
钙敏感受体激动剂增强三阴性乳腺癌中过继性NK细胞治疗的抗肿瘤活性
报告作者：Yu Shi
P2-06-23:Using a Machine Learning Model for Prediction of Palbociclib Response in a Single Institution，Real-World Analysis of Patients with ER+HER2-Advanced Breast Cancer
应用机器学习模型预测单中心真实世界中ER+/HER2-晚期乳腺癌患者对哌柏西利治疗的反应
报告作者：Xiaojie Zhang
P2-07-03:Noninvasive imaging of breast cancer and metastasis using TROP2-targeting radiotracer 68Ga-TTP
利用TROP2靶向放射性示踪剂68Ga-TTP对乳腺癌及其转移进行无创成像
报告作者：Yifei Pei
P2-07-14:Head-to-head comparison of the dual-targeting tracer[68Ga]Ga-RM26-RGD and[18F]FDG for PET imaging of breast cancer
双靶点示踪剂[68Ga]Ga-RM26-RGD与[18F]FDG在乳腺癌PET成像中的头对头比较
报告作者：Qingyao Shang
P2-07-27:Long-term administration of endocrine therapy on the gut microbiota of breast cancer patients between disease-free and recurrence
长期内分泌治疗对乳腺癌患者无病生存期与复发期间肠道微生物群的影响
报告作者：Ming-Feng Hou
P2-08-13:Effectiveness of Combined Neoadjuvant Pembrolizumab and Chemotherapy in Early Triple-Negative Breast Cancer:Real-World Evidence from Multiple Centers in Asia
早期三阴性乳腺癌中帕博利珠单抗联合新辅助化疗的疗效：来自亚洲多家中心的真实世界证据
报告作者：Yu-Ting Lin
P2-09-08:Correlating Breast Density with FDG-avidity on PET Imaging
乳腺密度与PET成像中FDG摄取程度的相关性
报告作者：YiLi Zhao
P2-09-11:Improved Prediction of Axillary Lymph Node Metastasis in Early-Stage Breast Cancer Using Deep Learning on Routine Mammography
利用深度学习常规乳腺钼靶检查改善早期乳腺癌腋窝淋巴结转移的预测
报告作者：Daqu Zhang
P2-09-17:Precision medicine based on similarity network fusion(SNF)subtypes of multi-omics in CDK4/6 inhibitor failed HR+/HER2-advanced breast cancer:the Linux trial
基于多组学相似性网络融合（SNF）亚型的精准医疗在CDK4/6抑制剂治疗失败的HR+/HER2-晚期乳腺癌中的应用：Linux试验
报告作者：Lei Fan
P2-09-28:Dalpiciclib plus endocrine therapy for visceral crisis in advanced breast cancer:a multicenter，prospective，external controlled phase 2 study
达尔西利联合内分泌治疗内脏危象的晚期乳腺癌：一项多中心、前瞻性、外部对照的II期研究
报告作者：Hongnan Mo
P2-10-01:Real-world Experience with CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic and Recurrent Breast Cancer in Asian Population
CDK4/6抑制剂在亚洲人群激素受体阳性转移性和复发性乳腺癌中的真实世界应用经验
报告作者：Bo-Fang Chen
P2-10-08:The Impact of Time-to-Surgery(TTS)for Breast Cancer Prognosis After Neoadjuvant Chemotherapy
新辅助化疗后手术时间（TTS）对乳腺癌预后的影响
报告作者：Xin Wang
P2-10-13:The Real World Practice of Prospectively Breast Cancer Screening Program for High Polygenic Risk Score Population in Taiwan
台湾针对高多基因风险评分人群的前瞻性乳腺癌筛查计划的实际应用情况
报告作者：Yu-Wen Weng
P2-10-16:A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment(YCT)
瑜伽治疗化疗所致周围神经病变的随机III期临床试验（YCT）
报告作者：Ting Bao
P2-11-01:Comprehensive spatially resolved single-cell analysis of immunotypes in triple-negative breast cancer revealed the central role of intratumoral MHC class II expressions
三阴性乳腺癌中免疫类型的全面空间分辨单细胞分析揭示了肿瘤内MHC II类表达的核心作用
报告作者：Yi Liu
P2-11-06:Neoadjuvant chemotherapy plus camrelizumab vs.chemotherapy in patients with locally advanced immunomodulatory triple-negative breast cancer:a prospective，randomized，open-label，phase 2 trial
局部晚期免疫调节性三阴性乳腺癌患者中新辅助化疗联合卡瑞利珠单抗与单纯化疗的比较：一项前瞻性、随机、开放性II期临床试验
报告作者：Li Chen
P2-11-13:Retrospective validation of digital twin-based prediction of personalized triple negative breast cancer response to neoadjuvant therapy regimens
基于数字孪生的个性化三阴性乳腺癌新辅助治疗方案反应预测的回顾性验证
报告作者：Chengyue Wu
P2-12-22:A multicenter，single-arm，phase II clinical trial of oral CDK4/6 inhibitor darciclib in combination with endocrine therapy in adjuvant treatment for hormone receptor-positive，HER2-negative female breast cancer.
口服CDK4/6抑制剂darciclib联合内分泌治疗辅助治疗激素受体阳性、HER2阴性女性乳腺癌的多中心、单臂、II期临床试验
报告作者：Jie Ouyang
P2-12-30:A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy treatment(ACT)
针灸治疗化疗所致周围神经病变的随机III期临床试验（ACT）
报告作者：Ting Bao
京公网安备 11010502033352号